Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.71 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.71 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 16/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.65 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118700 | 0.88 | TRAP1 (0.69) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL20118867 | 0.87 | ADORA2A (0.66) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL23388319 | 0.86 | ADORA2A (0.63) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL25548705 | 0.85 | TRAP1 (0.79) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL20118752 | 0.85 | HSP90AA1 (0.64) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL7197520 | 0.85 | HSP90AA1 (0.52) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL20118754 | 0.83 | TRAP1 (1.00) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL20118709 | 0.83 | TRAP1 (0.65) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL23416540 | 0.83 | TRAP1 (0.76) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL20118691 | 0.82 | HSP90AA1 (0.62) | HSP90AA1TRAP1HSP90AB1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629349-B2 | Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| EP-1349552-B1 | PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7087754-B2 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-20040116447-A1 | Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| EP-1349552-A1 | PYRAZOLO 3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055082-A1 | PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111373-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | CHRNA6, CHRNA5, CNR1 | HSP90AA1 4561/4885TRAP1 2843/4885HSP90AB1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.